Please ensure Javascript is enabled for purposes of website accessibility

Why Menlo Therapeutics Stock Sank Today

By Keith Speights – Updated Jun 5, 2020 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pricing of the biotech's stock offering weighed on shares.

What happened

Shares of Menlo Therapeutics (MNLO) were sinking 10.4% as of 3:20 p.m. EDT on Friday after dropping as much as 14% earlier in the day. The decline came after the company announced the pricing of a stock offering Friday morning. 

So what

Menlo plans to sell 27.05 million shares at $1.85 per share. The number of shares being offered represents nearly 20% of the total number of outstanding shares. The offering price reflects a 16% discount to the Thursday closing price for the biotech

$100 bills, stock chart, computer keyboard,

Image source: Getty Images.

Stocks usually fall on public offerings because the value of existing shares is diluted. It's actually a positive sign for Menlo that its stock fell by a lower percentage than the percent by which its shares are being diluted. That's probably a reflection of investors' optimism about the prospects of FCD105 after Menlo reported positive results earlier this week from a phase 2 study of that acne drug and won Food and Drug Administration approval for rosacea treatment Zilxi last week. It also helped that the overall stock market jumped today on better-than-expected job numbers.

Menlo expects to raise gross proceeds of around $50 million from the stock offering. This additional money should come in handy for the company as it launches Zilxi and advances its pipeline.

Now what

After launching acne drug Amzeeq earlier this year, the FDA's green light for Zilxi gives Menlo two approved products. The main things to watch in the near term are the company's next quarterly update in August and the expected commercial launch of Zilxi in the fourth quarter of this year. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Menlo Therapeutics Inc. Stock Quote
Menlo Therapeutics Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.